Ratings for Alnylam Pharmaceuticals ALNY -1.28% Get Free Report were provided by 18 analysts in the past three months, ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential. It declared on June 9 ...

The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce ...

ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with ...

The drug is already approved in the EU for transthyretin amyloidosis with polyneuropathy but now covers patients with cardiomyopathy.

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...

Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024, but roughly in line with levels seen in 2023 and 2022. Biopharma ...

Alnylam Pharmaceuticals Inc. won’t get another chance at its patent infringement suit against Moderna Inc. over its mRNA Covid-19 vaccine, a federal appeals court ruled Wednesday.

In a precedential decision issued June 4, 2025, the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed a district court's finding of noninfringement in favor of Moderna, Inc. in its ongoing ...

Moderna convinced a U.S. appeals court on Wednesday to uphold a ruling that undercut patent infringement claims by biotech ...